Tasimelteon for Autism and Sleep Disorders
Trial Summary
What is the purpose of this trial?
This trial is testing a daily pill called tasimelteon to help children and adults with Autism Spectrum Disorder (ASD) who have trouble sleeping. The medication aims to improve sleep by helping to regulate the body's internal clock.
Will I have to stop taking my current medications?
The trial requires that participants do not use medications that may cause sedation or stimulation, so you might need to stop taking such medications.
What data supports the effectiveness of the drug Tasimelteon for treating sleep disorders in autism?
Tasimelteon has been shown to help regulate sleep patterns in people with Non-24-Hour Sleep-Wake Disorder, especially in totally blind individuals, by aligning their sleep-wake cycles with the 24-hour day. This suggests it might also help with sleep issues in autism, as it works by targeting melatonin receptors to improve sleep-wake functions.12345
Is Tasimelteon safe for humans?
How is the drug Tasimelteon unique for treating autism and sleep disorders?
Tasimelteon is unique because it is a dual melatonin receptor agonist, specifically targeting the MT2 receptor to help regulate the body's internal clock, which is different from other treatments that may not focus on circadian rhythm adjustment. It is also the first drug approved for Non-24-Hour Sleep-Wake Disorder, highlighting its novel approach to sleep regulation.12367
Eligibility Criteria
This trial is for children and adults aged 2 to 65 with Autism Spectrum Disorder (ASD) who have trouble sleeping. Participants must be able to follow the study's rules and give consent, or have a guardian who can consent for them. They shouldn't have liver problems, drug abuse issues, or other sleep disorders caused by different conditions.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a daily single oral dose of tasimelteon to treat sleep disturbances
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Tasimelteon (Melatonin Receptor Agonist)
Tasimelteon is already approved in United States, European Union for the following indications:
- Non-24-Hour Sleep-Wake Disorder
- Nighttime sleep disturbances in Smith-Magenis Syndrome
- Non-24-hour sleep-wake rhythm disorder in totally blind adults